Revolution Medicines Starts Treating Patients in Phase 3 Trial for Zoldonrasib

MT Newswires Live10-20

Revolution Medicines (RVMD) has started treating adult patients in its global phase 3 clinical trial evaluating its investigational drug zoldonrasib on non-squamous non-small cell lung cancer, the company said Tuesday.

Zoldonrasib is being assessed in combination with standard of care pembrolizumab plus chemotherapy as a first-line treatment in adult patients with metastatic RAS G12D non-squamous non-small cell lung cancer.

The trial's primary endpoint is progression-free survival, while key secondary endpoints include overall survival, objective response rate, duration of response, safety and tolerability, and patient-reported outcomes, Revolution said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment